Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.31% | -209.21% | 52.30% | -- | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -46.94% | -- | -- |
| Total Other Non-Cash Items | 143.96% | 121.80% | -210.03% | -- | -- |
| Change in Net Operating Assets | -68.74% | 197.40% | -37.13% | -- | -- |
| Cash from Operations | 30.91% | 29.97% | -26.09% | -22.07% | -88.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -297.87% | 69.72% | 19.41% | -- | -- |
| Cash from Investing | -297.87% | 69.72% | 19.41% | -457.14% | -- |
| Total Debt Issued | 266.00% | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 75.05% | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 248.40% | -81.54% | 22.42% | 188.63% | 142.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.34% | -245.51% | 191.84% | 956.86% | 108.26% |